SCHEMBL9944490

SCHEMBL9944490

CC(C)(C)Cc1cccc(N2CCOCC2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 9/20 0.50
CXCR4 P61073 1/20 0.45
GAA P10253 2/20 0.44
CYP3A4 P08684 1/20 0.42
HTT P42858 1/20 0.41
KLKB1 P03952 1/20 0.41
KLK1 P06870 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10272910 0.83 PDE10A (0.53) PDE10ACXCR4GAAHTTKLKB1
SCHEMBL13171621 0.82 HTR3E (0.54) PDE10ACYP3A4HTTKDM4EALDH1A1
SCHEMBL6479913 0.80 PDE10A (0.49) PDE10ACXCR4GAAKLKB1KLK1
SCHEMBL29227340 0.80 PDE10A (0.50) PDE10ACXCR4GAAHTTKLKB1
SCHEMBL29866072 0.80 PDE10A (0.50) PDE10ACXCR4GAAHTTKMT2A
SCHEMBL1303138 0.80 PDE10A (0.50) PDE10ACXCR4GAAHTTKLKB1
SCHEMBL29907771 0.80 PDE10A (0.50) PDE10ACXCR4GAAHTTKLKB1
SCHEMBL1844501 0.80 PDE10A (0.50) PDE10ACXCR4GAAHTTKMT2A
SCHEMBL6475308 0.80 GAA (0.51) PDE10ACXCR4GAAHTTKLKB1
SCHEMBL13171555 0.79 HTR3E (0.56) PDE10AKMT2AHTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149683-A1 SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES MERCK SHARP & DOHME LLC 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149683-A1 SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES DPP4, DPP3, DPP7 PDE10A 1879/4885CXCR4 2859/4885GAA 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.